Your email has been successfully added to our mailing list.

×
0.0404040404040403 0.232323232323232 0.111111111111111 0.0909090909090909 -0.00101010101010101 -0.0708080808080808 -0.070808080808081 -0.071919191919192
Stock impact report

Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

Ritter Pharmaceuticals, Inc (RTTR)  More Company Research Source: GlobeNewswire
Last ritter pharmaceuticals, inc earnings: 8/14 05:11 pm Check Earnings Report
US:NASDAQ Investor Relations: ritterpharmaceuticals.com/investors
PDF LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first Food and Drug Administration (FDA)-approved treatment for lactose intolerance (LI), today provided an update of its Phase 3 clinical trial and regulatory efforts. The 557-subject Phase 3 clinical trial of RP-G28, known as “Liberatus”, remains on track with anticipated top-line data readout in early Q4 2019. As previously reported, all subjects have completed enrollment with last-patient-last-visit expected in July 2019. The study remains blinded and unblinding and analysis of the data will not take place until patients have completed all protocol periods and the database has been locked.  The Company has been in dialog with the FDA t [Read more]
Impact snapshot Event time: RTTR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
RTTR alerts
from News Quantified
Opt-in for
RTTR alerts

from News Quantified
Opt-in for
RTTR alerts

from News Quantified